George Yancopoulos & Regeneron Pharmaceuticals

George Yancopoulos: George Yancopoulos, co-Chair, President, and Chief Scientific Officer at Regeneron Pharmaceuticals, highlighted the significance of Dupixent's approval as a new standard of care for young children with chronic spontaneous urticaria.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals, in collaboration with Sanofi, developed Dupixent and received International — European Commission approval for its use in treating chronic spontaneous urticaria in young children, which is expected to boost its market position and revenue.

George Yancopoulos: George Yancopoulos, Board co-Chair, President and Chief Scientific Officer at Regeneron Pharmaceuticals, emphasized the significance of Dupixent's approvals and its role in treating type 2 inflammatory diseases.

Regeneron Pharmaceuticals: Regeneron Pharmaceuticals, in collaboration with Sanofi, developed Dupixent and received regulatory approvals for new indications, which is expected to positively impact its revenue and market position.

George Yancopoulos: George Yancopoulos is the co-Founder, Board co-Chair, President, and Chief Scientific Officer of Regeneron Pharmaceuticals, and the Innovator Award is named in his honor, reflecting his commitment to STEM.